Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation

Diabetes

Volumn 54, Issue 10, 2005, Pages 2939-2945

  Plomgaard, Peter ^a   Bouzakri, Karim ^b   Krogh Madsen, Rikke ^a   Mittendorfer, Bettina ^c   Zierath, Juleen R ^b   Pedersen, Bente Klarlund ^a,d  

^a University of Copenhagen   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Rigshopitalet 7641 ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTERIUM; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN KINASE B SUBSTRATE 160; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; ISOTOPE TRACING; LIFESTYLE; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADULT; DEUTERIUM; DRUG RESISTANCE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GTPASE-ACTIVATING PROTEINS; HUMANS; INSULIN; LIVER; MALE; MUSCLE, SKELETAL; PHOSPHORYLATION; PLACEBOS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25844456730     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.10.2939     Document Type: Article

References (45)

1. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7, 2004
2. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 52:1799-1805, 2003
3. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600, 2002
4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
5. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF alpha by human muscle: relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
6. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
7. Feingold KR, Grunfeld C: Role of cytokines in inducing hyperlipidemia. Diabetes 41 (Suppl. 2):97-101, 1992
8. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M: Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 52:119-123, 2001
9. Winkler G, Lakatos P, Nagy Z, Speer G, Salamon F, Szekeres O, Kovacs M, Cseh K: Elevated serum tumor necrosis factor-alpha and endothelin 1 levels correlate with increased C-peptide concentration in android type obesity (Letter). Diabetes Care 21:1778-1779, 1998
10. Nolle LA, Hansen PA, Chen MM, Schluter JM, Gulve EA, Holloszy JO: Short-term exposure to tumor necrosis factor-α does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes 47:721-726, 1998
11. Ranganathan S, Davidson MB: Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Metabolism 45:1089-1094, 1996
12. Patiag D, Gray S, Idris I, Donnelly R: Effects of tumour necrosis factor-alpha and inhibition of protein kinase Con glucose uptake in L6 myoblasts. Clin Sci (Lond) 99:303-307, 2000
13. de Alvaro C, Teruel T, Hernandez R, Lorenzo M: Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279:17070-17078, 2004
14. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996
15. Huang C, Thirone AC, Huang X, Klip A: Differential contribution of IRS-1 vs. IRS-2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 280:19426-19435, 2005
16. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614, 1997
17. Lechleitner M, Herold M, Dzien-Bischinger C, Hoppichler F, Dzien A: Tumour necrosis factor-alpha plasma levels in elderly patients with type 2 diabetes mellitus-observations over 2 years. Diabet Med 19:949-953, 2002
18. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human ahti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885, 1996
19. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ: No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316-1319, 2000
20. Kane S, Sano H, Liu SC, Asara JM, Lane WS, Gamer CC, Lienhard GE: A method to identify serine ktriase substrates: Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 277:22115-22118, 2002
21. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE: Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278:14599-14602, 2003
22. Zeigerer A, McBrayer MK, McGraw TE: Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol Biol Cell 15:4406-4415, 2004
23. van Hall G, Sacchetti M, Radegran G, Saltin B: Human skeletal muscle fatty acid and glycerol metabolism during rest, exercise and recovery. J Physiol 543:1047-1058, 2002
24. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205, 2004
25. Petersen AM, Pedersen BK: The anti-inflammatory effects of exercise. J Appl Physiol 98:1154-1162, 2005
26. Burrell R: Human responses to bacterial endotoxin. Circ Shock 43:137-153, 1994
27. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA: M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10:1165-1177, 2003
28. Vary TC, Deiter G, Lang CH: Diminished ERK 1/2 and p38 MAPK phosphorylation in skeletal muscle during sepsis. Shock 22:548-554, 2004
29. Plomgaard P, Keller P, Keller C, Pedersen BK: TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol 98:2019-2023, 2005
30. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R: Effects of tumor necrosis factor-α on insulin action in cultured human muscle cells. Diabetes 50:1102-1109, 2001
31. Youd JM, Rattigan S, Clark MG: Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-α. Diabetes 49:1904-1909, 2000
32. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y: A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272:29911-29918, 1997
33. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha. J Clin Invest 94:1543-1549, 1994
34. Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-9054, 2000
35. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF: Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537, 2002
36. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H: Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:1692-1697, 2005
37. Kim F, Gallis B, Corson MA: TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 280:01057-01065, 2001
38. Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG, Rattigan S: TNF-alpha acutely inhibits vascular effects of physiological but not high insulin or contraction. Am J Physiol Endocrinol Metab 285:E654-E660, 2003
39. Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C: Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108:1815-1821, 2003
40. Senn JJ, Hover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399, 2002
41. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED: Interleukin-6 (IL-6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser-473 of Akt. Am J Physiol Endocrinol Metab, 2005
42. Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784, 2003
43. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631-638, 2003
44. Mackay F, Kalled SL: TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 14:783-790, 2002
45. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829-1835, 1993